Evidence map›Paper›PMID 41107307›Full record

ArticleNPJ Parkinson's disease2025

Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation.

Francesco Bove, Danilo Genovese, Alessandro De Biase, Alberto Albanese, Angelo Antonini, Carlo Alberto Artusi, Laura Avanzino, Micol Avenali, Luca Baldelli, Giovanna Calandra-Buonaura and 29 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Francesco BoveNeurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Danilo GenoveseNeurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. danilo.genovese@guest.policlinicogemelli.it.
Alessandro De BiaseNeurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Alberto AlbaneseDepartment of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Angelo AntoniniPadova Neuroscience Center, University of Padua, Padua, Italy.
Carlo Alberto ArtusiDepartment of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy.
Laura AvanzinoDepartment of Experimental Medicine (DIMES), Section of Human Physiology, University of Genoa, Genoa, Italy.
Micol AvenaliDepartment of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Luca BaldelliDepartment of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Giovanna Calandra-BuonauraDepartment of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Ilaria CaniDepartment of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Niccolò CasasoliDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesco CavallieriNeurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Roberto CiliaParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Antoniangela CoccoDepartment of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Fabiana ColucciParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Francesca Di BiasioIRCCS Policlinico San Martino, Genoa, Italy.
Valentina D'OnofrioPadova Neuroscience Center, University of Padua, Padua, Italy.
Roberto EleopraParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Valentina FioravantiNeurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Giulia GianniniDepartment of Biomedical and NeuroMotor Sciences (DIBINEM), Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Nico Golfre' AndreasiParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Andrea GuerraPadova Neuroscience Center, University of Padua, Padua, Italy.
Gabriele ImbalzanoDepartment of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy.
Alessandro IzzoNeurosurgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Claudia LeddaDepartment of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy.
Marco LiccariClinical Unit of Neurology, Department of Medical, Surgical and Health Sciences, Cattinara University Hospital, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), Trieste, Italy.
Leonardo LopianoDepartment of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy.
Maria Chiara MalagutiDepartment of Neurology, Santa Chiara Hospital, Trento, Italy.
Raffaella MinardiIRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura, 3, 40139, Bologna, Italy.
Pierfrancesco MitrottiDepartment of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Luigi Michele RomitoParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Enza Maria ValenteIRCCS Mondino Foundation, Pavia, Italy.
Franco ValzaniaNeurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Roberta ZangagliaIRCCS Mondino Foundation, Pavia, Italy.
Paolo CalabresiNeurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Carla Piano *Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Anna Rita Bentivoglio *Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Italian PARKNET Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GBA1 variants represent the most common genetic risk factor for Parkinson's disease (PD) and are associated with higher risk of developing cognitive decline and axial motor impairment. While cognitive outcomes following subthalamic deep brain stimulation (STN-DBS) have recently received growing attention, axial signs progression remains poorly defined in this population. In this retrospective multicentric study, we analyzed a cohort of 353 PD patients who underwent bilateral STN-DBS surgery (75 GBA+ and 253 GBA-). 5-year follow-up data were available for 233 patients, including 43 mutated subjects. Lower off-medication UPDRS III score and levodopa responsiveness at baseline were identified as independent predictors of axial signs worsening after DBS, while GBA1 genotype was not identified as risk factor. The presence of GBA1 variants did not exert a detrimental effect on axial signs in PD patients up to five years following STN-DBS, supporting its consideration as a valid therapeutic option in this genetic subgroup.

Identifiers

PMID41107307
PMCPMC12534511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.